Author: NDTV News Desk

REYKJAVIK, ICELAND (January 29, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes worldwide related to Alvotech’s biosimilar to Eylea® 2mg (aflibercept 40 mg/mL solution), which is approved for marketing in the European Economic Area, United Kingdom aRead More

Read More

As European markets navigate renewed trade and geopolitical uncertainty, with the pan-European STOXX Europe 600 Index ending 0.98% lower, investors are keenly observing high-growth tech stocks that could potentially thrive in this environment. In such a climate, a good stock is often characterized by its ability to adapt to changing market conditions and leverage technological advancements to maintain robust growth trajectories amidst broader economic challenges.Read More

Read More